Business
CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
PRINCETON, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the
About this update from Cytosorbents Corporation
[{"type":"text","content":"PRINCETON, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it will host its Virtual Annual Stockholders Meeting tomorrow, June 6, 2023 at 10AM EDT. Separately, Chief Executive Officer Dr. Phillip Chan will present at the Jefferies Healthcare Conference in New York City on Friday, June 9, 2023 from 11:30-11:55AM EDT. The in-person conference is by invitation only, but other investors may log into the live webcast, which will also be available for 90 days after the event. To schedule a 1x1 meeting with management, please contact your Jefferies representative. CytoSorbents Corporation Virtual Annual Stockholder MeetingWhen: Tuesday, June 6, 2023 at 10:00AM EDTWebcast: CytoSorbents Webcast Link (by Broadridge)Requirements: As described in the proxy materials previously distributed, stockholders as of the close of business on April 13, 2023, the record date, are entitled to participate in the Annual Stockholders Meeting. To participate, stockholders will need the 16-digit control number included in the proxy materials delivered previously. Jefferies Annual Healthcare Conference When: Friday, June 9, 2023 from 11:30AM-11:55AM EDT Webcast: CytoSorbents Jefferies Presentation Webcast Link About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces \"cytokine storm\" or \"cytokine release syndrome\" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. At the end of Q1 2023, more than 203,000 CytoSorb devices had been used cumulatively. CytoSorb was originally launched in the European Union...